Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, Heinz August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortes, Angelo Michele Carella, Miklos Egyed, Utz Krug, Judith A. Fox, Adam R. Craig, Renee WardJennifer A. Smith, Gary Acton, Hagop M. Kantarjian, Robert K. Stuart

Research output: Contribution to journalLetter

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)e514-e518
JournalHaematologica
Volume103
Issue number11
DOIs
StatePublished - Oct 31 2018

ASJC Scopus subject areas

  • Hematology

Cite this

Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E., Pigneux, A., Horst, H. A., Récher, C., Klimek, V. M., Cortes, J. E., Carella, A. M., Egyed, M., Krug, U., Fox, J. A., Craig, A. R., ... Stuart, R. K. (2018). Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica, 103(11), e514-e518. https://doi.org/10.3324/haematol.2018.191361